Teva draws up mid-stage study plans for vitiligo asset on Phase Ib success

Teva plans to start a Phase IIb study on TEV-‘408 in vitiligo during the final quarter of 2026 following positive results of a Phase Ib trial. Teva plans to start a Phase IIb study on TEV-‘408 in vitiligo during the final quarter of 2026. Teva will progress vitiligo candidate, TEV-‘408 into Phase IIb trials following positive Phase Ib results. Credit: Doralin Samuel Tunas / Shutterstock.com. Teva is planning to progress its anti-IL-15 therapy, TEV-‘408 into a Phase IIb trial in vitiligo after the drug demonstrated promise in an ongoing Phase Ib open-label study. The Phase Ib trial enrolled adults with…

Source: Clinical Trials Arena